Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Personnel Changes

22nd Sep 2006 10:19

Skyepharma PLC22 September 2006 For Immediate Release 22 September, 2006 SkyePharma PLC SkyePharma to Reorganise Certain Management Functions LONDON, ENGLAND, 22 September, 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE)announces today that as part of the Company's ongoing initiatives to increaseoperational efficiency the Board has decided to out-source investor relationsand to restructure the legal and company secretarial functions. By mutualagreement Peter Laing, Director of Corporate Communications, and DouglasParkhill, Company Secretary, will be leaving the Company. Frank Condella, SkyePharma's Chief Executive, said: "We thank Peter and Douglasfor their meritorious service in their respective roles and wish them everysuccess in the future." For further information please contact: SkyePharma PLC +44 207 491 1777Frank Condella, Chief Executive Officer Buchanan Communications +44 207 466 5000Tim Anderson / Mark Court / Rebecca Skye Dietrich The Trout GroupSeth Lewis +1 617 583 1308 Notes for editors About SkyePharma SkyePharma PLC develops pharmaceutical products benefiting from world-leadingdrug delivery technologies that provide easier-to-use and more effective drugformulations. There are now eleven approved products incorporating SkyePharma'stechnologies in the areas of oral, injectable, inhaled and topical delivery,supported by advanced solubilisation capabilities. For more information, visitwww.skyepharma.com. Certain statements in this news release are forward-looking statements and aremade in reliance on the safe harbour provisions of the U.S. Private SecuritiesLitigation Act of 1995. Although SkyePharma believes that the expectationsreflected in these forward-looking statements are reasonable, it can give noassurance that these expectations will materialize. Because the expectations aresubject to risks and uncertainties, actual results may vary significantly fromthose expressed or implied by the forward-looking statements based upon a numberof factors, which are described in SkyePharma's 20-F and other documents on filewith the SEC. Factors that could cause differences between actual results andthose implied by the forward-looking statements contained in this news releaseinclude, without limitation, risks related to the development of new products,risks related to obtaining and maintaining regulatory approval for existing, newor expanded indications of existing and new products, risks related toSkyePharma's ability to manufacture products on a large scale or at all, risksrelated to SkyePharma's and its marketing partners' ability to market productson a large scale to maintain or expand market share in the face of changes incustomer requirements, competition and technological change, risks related toregulatory compliance, the risk of product liability claims, risks related tothe ownership and use of intellectual property, and risks related toSkyePharma's ability to manage growth. SkyePharma undertakes no obligation torevise or update any such forward-looking statement to reflect events orcircumstances after the date of this release. This information is provided by RNS The company news service from the London Stock Exchange

Related Shares:

SKP.L
FTSE 100 Latest
Value9,120.31
Change-18.06